| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To be able to survive and proliferate, tumor cells need to escape the human immune defense mechanisms, including the cytolytic C system. As on normal nucleated cells, the activation of C on tumor cells is usually regulated at two steps by cell surface proteins. The C3/C5 convertases are inhibited by decay-accelerating factor (CD55) and membrane cofactor protein (MCP, CD46),4,5 and formation of the C membrane attack complex is inhibited by a low molecular weight protein called MACIF, MIRL, or protectin (CD59).6,7 Protectin inhibits the C transmembrane channel formation by binding to C components C8 and C9 and preventing C9 polymerization.8,9 The glycophosphoinositol-anchored protectin is widely and abundantly distributed in normal tissues in the body.10 High expression levels have also been found on most types of malignant cells studied to date.11-17
Our earlier studies have shown that by inactivating protectin with the monoclonal anti-CD59 antibody YTH53.1, it is possible to increase the sensitivity of breast carcinoma (T47D and MCF7), melanoma (G361), and glioma cells to C lysis.13,14,17 However, because malignant cells usually grow as multicellular tumors in vivo, complicating factors such as intercellular connections between the tumor cells may constitute an additional barrier against C attack. Cell lysis by complement involves the sequential activation of 11 different proteins in the classical pathway. If not restricted, C activation becomes amplified and can spread to nearby areas during progression of the classical pathway and by recruitment of the alternative pathway. So far, little information is available concerning the ability of C components to penetrate into three-dimensional tissue. As C-mediated tissue destruction is difficult to study in vivo, we have set up a microtumor spheroid (MTS) model to study C activation and penetration of C components into the tumor tissue. MTSs are spherical aggregates of cells growing in culture. Their size may range from a few cells to visible structures of 1 to 2 mm in diameter until the growth is limited by restricted diffusion of oxygen and nutrients. Cells growing in MTS resemble tumor tissue with their intercellular connections.18 As such, they represent an intermediate between monolayer cell cultures and tumors in vivo.19 Spheroids have been used to study the penetration of antibodies and the optimization of radioimmunotherapy, as well as the effect of lymphokine-activated killer cells against tumor tissue.20-24
We have established MTS from the T47D breast carcinoma and PA-1 teratocarcinoma cell lines. Our previous study indicated that PA-1 cells in spheroids were more resistant to C lysis than PA-1 cells growing in suspension.25 During a standard 30-minute incubation, the C components became deposited on the MTS surface but did not lead to significant cell killing. In the present study, we wanted to find ways to overcome the C resistance of MTS. We examined whether it is possible to kill cells in the spheroids by neutralizing the membrane attack complex inhibitor protectin, prolonging the time of C exposure, and by replacing C that may become consumed during short-term incubations. C killing of cells in spheroids necessitates that C components penetrate into the tumor tissue. To determine the limiting step in C attack against spheroids, we analyzed how the C components C1q, C3, and C5b-9 became deposited on the various cell layers in the spheroids during a pulsed and prolonged C treatment. By using different labeling methods, we were able to simultaneously monitor C penetration, changes in cell membrane permeability, and cell detachment.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A murine monoclonal antibody (mAb) to human CD59 (BRIC229) was
purchased from Bio-Products Laboratory (Elstree, UK). A cell line
producing a rat mAb against CD59 (YTH53.1) was originally obtained from
Prof. H. Waldmann (Sir William Dunn School of Pathology, Oxford, UK).
The isolation and biotinylation of YTH53.1 (immunoglobulin (Ig) G2b)
have been described previously.26
Purified rat
immunoglobulins were purchased from Sigma Chemical Co. (St. Louis, MO).
Rabbit antiserum to human breast cancer cells (S2) was raised by
immunizing a rabbit three times with 107
heat-killed MCF7
(breast adenocarcinoma) cells intramuscularly.13
S2 IgG was
isolated by protein G affinity chromatography (Pharmacia-LKB
Biotechnology, Uppsala, Sweden). The potential inherent anti-CD59
reactivity of the S2 IgG was removed by absorbing the IgG with human
erythrocytes. IgG isolated from a preimmunization serum (S0) of the
rabbit was used as a control antibody. Mouse mAb to human iC3b
neoantigen and goat antiserum to human C1q were from Quidel Corp. (San
Diego, CA). Mouse mAb (Wu) to C5b-9 was kindly obtained from Dr. R.
Würzner (University of Innsbruck, Innsbruck, Austria). Mouse mAbs
(IgG1) to human Fc receptors: Fc
RI (clone 10.1), FcRII (clone
C1KM5), and FcRIII (clone 3G8) were obtained from Caltag
Laboratories (Burlingame, CA). Fluorescein isothiocyanate
(FITC)-conjugated antibodies to rabbit Igs were purchased from Jackson
ImmunoResearch Laboratories (West Grove, PA). FITC-conjugated rat
antibody to mouse IgG was from Boehringer Mannheim Biochemicals
(Indianapolis, IN). FITC-conjugated antibody to rat immunoglobulins was
obtained from DAKO A/S (Glostrup, Denmark). Normal human serum (NHS)
that served as a source of complement was prepared from coagulated
blood of healthy volunteers and stored at -70°C until used.
Cell Lines and Generation of Spheroids
A human ductal breast carcinoma cell line, T47D,27 and an ovarian teratocarcinoma cell line, PA-1,28 were obtained from American Type Culture Collection (Manassas, VA). Cells were maintained in culture in RPMI 1640 (Gibco, Paisley, UK) supplemented with 10% fetal calf serum, 2 mmol/L L-glutamine, and antibiotics (10 U/ml penicillin and 100 mg/ml streptomycin) at 37°C in humidified air with 5% CO2. Cells were grown as monolayers in 75-cm2 cell culture flasks until confluent and trypsinized into suspension. T47D and PA-1 spheroids were cultured by a modification of a liquid overlay technique.18 The growth of the spheroids was initiated by plating 2 x 103 cells per well in 200 µl of RPMI 1640 on 96-well U-bottomed microtiter plates (Costar, Cambridge, MA) coated with a thin layer of 0.5% agarose. The agar prevented the attachment of the cells to the plate, resulting in the formation of one spherical cell aggregate per well. Individual spheroids were grown for 10 to 14 days. Spheroids selected for the experiments were photographed and scanned from the negatives with an AGFA Arcus II color scanner. The scanned spheroids were analyzed using the NIH Image program (developed at the National Institutes of Health) and a Power Macintosh 7200/90 computer to determine the diameters and volumes of the particles. Some of the spheroids were trypsinized to count the cell number.
Chromium Release Assay for Spheroids
C-mediated cytotoxicity against tumor cells growing in spheroids was determined by a chromium release assay. T47D or PA-1 spheroids were individually labeled with 3 µCi of sodium chromate (51Cr; Amersham International, Buckinghamshire, UK) in 100 µl of RPMI 1640 for 12 hours at 37°C. To remove the unbound or loosely bound 51Cr, MTSs were washed three times with the cell culture medium and incubated for a further 60 minutes. The washing procedure was repeated, and the spheroids were finally placed into 50 µl of RPMI 1640 in test tubes. Each spheroid was counted for total radioactivity. In the killing assay, the spheroids were incubated with S2 (50 µg/ml) and/or YTH53.1B (25 µg/ml) and NHS (1/2) in a total volume of 200 µl. In the controls, either antibodies and NHS were omitted (spontaneous 51Cr release) or S0 and normal rat IgG were used instead of S2 and YTH53.1B, respectively. In the standard assay, the spheroids were incubated with the lysis medium for a total of 24 hours at 37°C. During the incubation, at 2, 4, and 8 hours, the spheroids were isolated gently by pipetting and placed into new tubes containing fresh NHS and antibodies to replace the C components and IgG consumed. In a prolonged assay, the incubation was extended to 50 hours, and fresh NHS and antibodies were added either at 2, 4, 8, 16, and 24 hours or at 4-hour intervals. The 51Cr released into the medium was counted in a gamma counter. Finally, after incubation, each spheroid was isolated and counted for the remaining radioactivity. The cell lysis was determined as a cumulative release of 51Cr into the cell culture medium from each spheroid and calculated as a percentage of the total initial radioactivity: ((Released radioactivity - spontaneous release)/(Total radioactivity - spontaneous release)) x 100%. The Student's two-tailed t-test was used to test the significance of differences between mean values.
Scanning Electron Microscopy
Scanning electron microscopy was used for the visualization of the effects of complement exposure to the microtumors. Variously treated spheroids were fixed with 2.5% glutaraldehyde in phosphate-buffered saline (PBS) for 2 hours and washed thereafter with PBS for 30 minutes. The samples were dehydrated in an ascending series of graded ethanol, dried in a Balzers CPD 030 critical point dryer (Balzers, Liechtenstein) and coated with a 20-nm layer of platinum in an Agar Sputter Coater (Agar Scientific Ltd., Stanstedt, UK). Finally, the spheroids were examined with a Zeiss DSM 962 scanning electron microscope (Oberkochen, Germany) using a secondary electron image at 20 kV.
Evaluation of C Damage and Penetration of C Components into Spheroids by Immunofluorescence Microscopy
Cell damage resulting from the exposure of the MTS to C was visualized by the uptake of propidium iodide (PI; Sigma) into cells with membrane lesions. MTSs were harvested after 10 to 14 days of culture and washed by gravitation in a test tube three times through 10 ml of RPMI 1640. Individual T47D spheroids were incubated with the nonbiotinylated YTH53.1 mAb (25 µg/ml) and/or S2 (50 µg/ml) and NHS (1:2) in a total volume of 200 µl in the wells of 96-well microtiter plates at 37°C. In the controls, S0 and purified rat IgG were used instead of S2 and YTH53.1. The spheroids were photographed before and after a 24-hour incubation with NHS and antibodies to determine the change in their volume after complement damage. At 2, 4, and 8 hours, some of the spheroids were isolated, and fresh NHS and antibodies were added to the remaining spheroids. One hour before each sample removal, 50 µg/ml of PI was added into the incubation medium to detect changes in cell membrane permeability. Washed spheroids were embedded in Tissue-Tek OCT (Miles Inc., Elkhart, IN), frozen and sectioned (5 to 10 µm) in a cryostat. The PI-stained sections were examined using an Olympus BX50-FLA reflected light fluorescence attachment microscope (Olympus Optical Co., Ltd., Tokyo, Japan).
For the analysis of C component penetration by immunofluorescence
microscopy, the sections of variously treated spheroids were fixed with
4% paraformaldehyde and treated with 1% bovine serum albumin
(fraction V, Sigma) in PBS to prevent nonspecific binding. Thereafter,
the sections were incubated with appropriate dilutions of antibodies to
human C components in a humidified chamber. Bound antibodies were
detected with FITC-conjugated secondary antibodies against rabbit,
mouse, goat, or rat IgG. Background immunofluorescence was assessed by
omitting the primary antibodies. The possible expression Fc receptors
(FcRI, FcRII, and FcRIII) on T47D cells was performed
similarly by using immunofluorescence microscopy, and the respective
mAbs. After the staining procedure, the sections were mounted in
Mowiol29
and examined using the Olympus fluorescence
microscope.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
T47D and PA-1 cell spheroids were grown for up to 14 days using the liquid overlay technique. Single cells plated on the agarose-coated 96-well plates began to adhere to each other, forming irregular aggregates (one aggregate per well) during an overnight incubation. After 7 days of incubation, both T47D and PA-1 MTS were uniformly spherical and regular in shape. Spheroids grown for more than 14 days began to develop necrotic centers as determined by PI staining. T47D spheroids had a tendency to develop necrotic centers earlier than PA-1 spheroids. The tendency for cell-to-cell adhesion in the T47D spheroids was strong. The cells required a 1-hour trypsinization and mechanical disintegration by pipetting to become separated. Ten-day-old spheroids selected for the experiments had a mean diameter of 0.719 ± 0.02 mm and a calculated volume of 0.194 ± 0.063 mm3 (mean ± SD; n = 40) as determined from the scanned images. The number of cells counted from the trypsinized spheroids was 2.1 x 105 ± 2200 cells/spheroid (mean ± SD).
51Chromium Release from Microtumors Exposed to Antibodies and C
To quantify C-mediated death of cells in the spheroids a chromium (51Cr) release assay was used. Individual T47D spheroids were incubated with 3 µCi of 51Cr for 12 hours in 100 µl of cell culture medium. Earlier studies by autoradiography have demonstrated that an overnight incubation leads to penetration of 51Cr throughout the spheroids.24 After washes, the emission of radioactivity was 11,181 ± 376 cpm/spheroid (mean ± SD; n = 20). The mean cumulative spontaneous release of chromium during a 24-hour incubation of spheroids in the RPMI 1640 containing 10% heat-inactivated fetal calf serum was 13% ± 0.6% of the total radioactivity (n = 4). This is in correlation with the total remaining activity (90 ± 1.2%) that was counted from each spheroid after the 24-hour incubation. The spontaneous release of chromium was considered as background and was subsequently subtracted from the further results.
To study C-mediated killing of T47D spheroids, the S2 antibody was used
for activation of the classical pathway of C and the biotinylated
YTH53.1 mAb (YTH53.1B) for neutralization of the membrane attack
complex inhibitor CD59 on the cells. YTH53.1 is a rat mAb (IgG2b) that
is capable of activating human C. However, biotinylation of YTH53.1
prevents it from activating the classical pathway of complement while
retaining its original affinity for CD59.26
A 24-hour
incubation with antibodies and a single dose of NHS resulted in the
release of 16 ± 4% (Figure 1A)
of
the spheroid-bound radioactivity. In another set of experiments, to see
the effect of C replenishment to the spheroid lysis and to study the
kinetics of C lysis, NHS and the antibodies were replaced at 2, 4, and
8 hours, and cumulative 51Cr release was measured during
the assay at the same time points. In the killing assay, there was a
clear lag phase in the 51Cr release during the first 2
hours of incubation (Figure 1B)
. T47D spheroids exposed to S2,
YTH53.1B, and NHS for 2 hours showed only 1% lysis. At 4 hours, 5%
lysis was achieved. A more significant lysis was not detected until 8
hours of incubation (15 ± 0.5%; n = 4). The mean
(±SD) cumulative release of chromium from the spheroids exposed to S2,
YTH53.1B, and NHS during 24 hours of incubation was 33% ± 2.3%
(Figure 1B)
, whereas 62 ± 0.45% of 51Cr was counted
to remain in the spheroids. In the control spheroids incubated with S0,
normal rat IgG, and NHS for 24 hours (with replacements), the mean
cumulative activity released was only 3 ± 0.96%
(n = 4) more than the spontaneous release during
the same time. In the spheroids exposed to either S2 or YTH53.1B and
NHS, the mean cumulative 51Cr releases were 4 ± 1.5%
and 5 ± 0.6%, respectively (n = 8).
|
. The increase in the
number of C replacements to a total of 11 at 4-hour intervals during 50
hours of incubation did not significantly enhance the tumor cell lysis
either (Figure 1D)
. After 50 hours of C exposure, the C-treated
spheroids were plated on cell culture plates. An overnight incubation
resulted in the adherence and spreading of the T47D cells over the
plate bottoms, indicating that the spheroids still contained viable
cells. Effect of C Treatment on the Volume of T47D Spheroids
To determine the effect of C treatment on the microtumor volume,
individual T47D spheroids were incubated on the 96-well culture plates
with S2, YTH53.1B, and NHS with replacements at 2, 4, and 8 hours.
After a 24-hour incubation, the surfaces of the spheroids were clearly
less coherent and cells more swollen than before the incubation, as
determined by light microscopy (Figure 2, A and B)
. As judged from photographic images, the volume of the
spheroids decreased by 28% from 0.194 ± 0.063 to 0.140 ±
0.05 mm3
(mean ± SD; n = 30) during
the 24-hour pulsed treatment with antibodies and C. The volume of the
control spheroids exposed to S0, normal rat IgG, and NHS decreased by
only 5% during the 24-hour incubation (residual volume, 0.185 ±
0.013 mm3). Scanning electron microscopic analysis after
the C exposure showed a release of relatively large vesicles from the
cell surfaces and porous remnants of cell membranes after severe cell
damage (Figure 2, D and F)
. No similar changes were detected in the
control spheroids incubated with NHS, S0, and normal rat IgG (Figure 2, C and E)
. In these controls, the surface of the microtumors remained
smooth with a fine microvillar coating.
|
To visualize death of individual cells in the spheroids, some of
the spheroids treated for various times with S2, YTH53.1B, and NHS were
incubated for 1 hour with PI before freezing into liquid nitrogen.
Fluorescence microscopical analysis of cryostat sections of the PA-1
spheroids showed a two to three-cell layer-thick frontier of dying
cells on the microtumor surfaces after 2 hours of C exposure (Figure 3A)
. Apparently, some of the cells had
become detached from the spheroid surface. In the control microtumors
incubated with S0, nonspecific rat IgG, and NHS, no dead cells were
observed on the microtumor surfaces (Figure 3B)
. By comparison, in the
T47D microtumors the rim of dead cells did not extend deeper than one
or two cell layers from the surface after 2 hours of incubation (see
Figure 5E
). Furthermore, the cells still remained firmly attached to
the microtumor tissue. After 8 hours of exposure to C, the damaged T47D
cells on the surface remained adherent to the spheroidal body. After 24
hours of incubation, the PI staining revealed a large pool of damaged
cells detaching from the surfaces of the spheroids (see Figure 5F
). The
necrotic cells in the centers of the largest spheroids also became
stained by PI. In the control spheroids that were exposed to S0, normal
rat IgG, and NHS, only the necrotic cells in the center became stained,
but no killing of cells on the surface was detected (see Figure 5I
).
This indicated that PI was able to penetrate into the center of the
spheroids through the intercellular spaces.
|
|
During a 2-hour incubation, the YTH53.1 mAb penetrated into the
spheroid tissue as a frontier and infiltrated four to five cell layers
deep (Figure 4A)
. After an overnight
exposure to YTH53.1 and NHS, the T47D spheroids became totally
infiltrated by the YTH53.1 IgG (Figure 4B)
. Somewhat surprisingly,
although C1q has a relatively large size (molecular weight 460 kd), it
was able to penetrate two to three cell layers deep during a 2-hour
exposure to YTH53.1 and NHS (Figure 4C)
and almost through the
spheroids over 24 hours (Figure 4D)
. The penetration of S2 was slower
compared with the infiltration of the YTH53.1 mAb. In 2 hours, the S2
IgG was able to penetrate only through the first two cell layers
(Figure 4E)
. After 24 hours, the S2 IgG penetrated deeper, forming a
gradient toward but not up to the core of the spheroids (Figure 4F)
. In
the controls incubated with rat IgG, rabbit preimmune IgG (S0), and
NHS, no deposition of nonspecific rat IgG (Figure 4G)
, C1q (Figure 4H)
or rabbit IgG (Figure 4I)
could be detected. To exclude the possibility
that antibodies bound to Fc receptors, we used 10.1, C1KM5, and 3G8
mAbs for staining of FcRI, FcRII, and FcRIII on T47D cells,
respectively. No binding of any of these mAbs to the T47D cells was
detected.
|
Immunofluorescence analysis showed that C3 (stained with the
anti-iC3b antibody) and C5b-9 deposits remained peripheral in the
spheroids and were restricted to the outermost one to two cell layers
after 2 hours (Figure 5, A and C)
and two
to four cell layers after 24 hours (Figure 5, B and D)
of C exposure.
PI staining was in accordance with the staining for C3 and C5b-9,
revealing that the C-mediated killing of the cells was limited to the
microtumor surface (Figure 5, E and F)
. In the controls, in which S0,
nonspecific rat IgG, and NHS were used, no deposition of C3 (Figure 5G)
or C5b-9 (Figure 5H)
was detected after 24 hours of incubation.
Accordingly, no C-mediated cell death was seen on the surfaces of
similarly treated microtumors (Figure 5I)
.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
So far, little is known about the ability of C components to penetrate
into solid tumor tissue. Earlier, we observed that in traditional
killing assays, cells growing in aggregates were notably more resistant
to C-mediated cytotoxicity than cells in suspension.25
In
the present study, we wanted to find out reasons for this resistance
and develop potential ways to overcome it. After neutralizing protectin
(CD59), the main inhibitor of C lysis, with a specific mAb, and
initiating C activation with a polyclonal antibody, lysis of cells in
the spheroids started to occur after a 1 to 2-hour lag period. By
prolonging the time of exposure and replacing the C components
consumed, we were able to partially overcome the C resistance of the
ductal breast carcinoma (T47D) and ovarian teratocarcinoma (PA-1)
spheroids. During a 24-hour exposure to C, the release of
51Cr was 33% from the T47D spheroids. Prolonging the
incubation time did not further significantly increase the level of
lysis, and a plateau phase was reached after 42 hours (Figure 1, C and D)
. However, because the spontaneous release of 51Cr was
30% at 48 hours, the assay may not have revealed the full extent of
cell damage during prolonged incubations.
The main reasons for the observed lag-phase are probably a limited initial penetration of antibodies and C components through the MTS surface and consumption of active C on the outer layers of the spheroids. It is likely that the delivery of C components and mAb into the spheroids occurs by diffusion through the intercellular spaces. In an earlier study, mAbs were found to be capable of penetrating into the MTS.20 This was the case with the YTH53.1 mAb that infiltrated through the spheroids during an overnight incubation. However, BRIC 229, another mAb against CD59, did not completely pass through the spheroids during the same time (data not shown). Because of stronger binding to target antigens, antibodies of higher affinity are predicted to diffuse more slowly into the tumor.
C treatment did not completely disrupt the macroscopic structure of the MTS. The cores of the spheroids retained their integrity during incubation with antibodies and C for 24 hours. It was thus possible to efficiently kill cells growing on the surface of the spheroids, but cells deeper inside were protected from C lysis. The plating of the spheroids after 50 hours resulted in the adherence and spreading of the cells over the cell culture plate surface, indicating that the spheroids still contained viable cells. Our results indicate that the resistance of cancer cells growing in the cores of the spheroids to C-mediated injury results at least partly from the restricted spreading of C3 activation into the spheroids. The first component of the classical pathway of C, C1q, was able to penetrate almost through the spheroids within 24 hours despite its rather high molecular weight (462 kd). The binding of C1q to the Fc part of an antibody is noncovalent.30 During C activation, the forming C3b binds covalently with a thioester bond to a nearby cell surface. Although C1q can diffuse relatively freely through the spheroid, the penetration of C3 is limited, first, by rapid activation and covalent binding and, thereafter, by rapid inactivation of C3b. Restricted penetration of C3 is thus not due to a limited diffusion but because of its specific biochemical properties.
A reason that can restrict C activation to the spheroid surface in our model is an effective C regulation at the C3 level. In these studies, we did not attempt to neutralize MCP or decay-accelerating factor, which both down-regulate C3 activation on cell surfaces. Because of its stronger expression on the spheroids,25 MCP is likely to promote inactivation of both C4b and C3b that have become bound to the tumor cell surfaces. Thus, MCP could effectively block both the classical and the alternative pathway C3 convertase function. Further optimization of C killing in our model should thus include inactivation of the activity of MCP.
After C exposure, the surfaces of the spheroids became clearly less coherent, showing swollen and detaching cells as judged by light microscopy. Scanning electron microscopy revealed damaged cells with remnants of cell membranes on the microtumor surfaces. The nuclei of escaping cells were visible in the PI-stained specimens. New cell layers became exposed to C after the dead cell layer had been peeled off during the process. The cell death thus proceeded as a frontier but was restricted mainly to the first four layers of cells on the periphery of the spheroids after a 24-hour exposure. This was consistent with findings of the penetration of C3 and C5b-9, which also remained limited to the surface of the MTS. After a 2 to 8-hour-long exposure of MTS to C, the PI-stained, apparently dead T47D cells were still firmly attached to the spheroids. After 24 hours of exposure, a necrotic rim of cells and many detaching cells were observed in the PI-stained sections.
The detachment of cells from the spheroid surface may be due to down-regulation of adhesion receptors and/or proteases released from the dying or sublytically attacked tumor cells. The proteolytic enzymes may start to degrade the extracellular matrix and proteins required for the cellular adhesion. Activation of metalloproteinases and degradation of extracellular matrix occur during various physiological and pathological processes. These include conditions that require tissue remodeling such as tissue morphogenesis, inflammation, and wound healing. On the other hand, eg, the C serine esterase C1s has been shown to degrade type I and type II collagens31 and to activate the zymogen form of the matrix metalloproteinase 9 enzyme.32 The released proteases might also activate or inactivate C components and thereby have an enhancing or inhibitory effect on C killing of the microtumor cells. Leukocyte matrix metalloproteinases have been shown to inactivate C1 inhibitor that inactivates the C1r and C1s proteinases.33,34 On the other hand, the metalloproteinases could decrease complement resistance of the spheroids by degrading inhibitors of C on the cell membranes.
C3 deposition on tumor cells may have multiple consequences on the immune responses against the tumors. The cleavage fragments of C proteins (C3a, C4a and C5a) generated during the activation are released into the fluid phase. These small bioactive peptides act as chemotaxins, leukocyte activators, and anaphylatoxins.35 The larger fragments of C proteins (C3b and C4b) bind covalently to the activating targets, opsonizing them for phagocytosis. The phagocytic cells have cell membrane receptors that interact with C3b and C4b to allow clearance of the activating particles.36 C3 deposition may also increase the antigenicity of the potential tumor antigens on the tumor cells. Dempsey et al37 have shown in their study that tethering C3d into hen egg lysozyme lowered the threshold level of the B-cell response to lysozyme, thereby increasing its immunogenecity.37 Thus, C3d can act as a molecular adjuvant and may be able to increase tumor antigen immunogenicity as well.
Micrometastases and residual malignant cells after surgery constitute an important clinical problem in cancer therapy. The approach of using C against tumors in vivo is currently limited by the lack of tumor cell-specific and C-activating antibodies. Many of the mAbs that are produced in murine hybridoma cell lines belong to the IgG1 subclass that in general is a poor activator of human complement. Another problem is the activity of C regulators on the malignant cells. However, as implied by our earlier studies, it is possible to specifically target C attack against tumors if suitable mAbs are available.14 As shown here, mAbs and even large C molecules, such as C1q, can penetrate into the tumor tissue. Destruction of microtumors could thus be achieved by neutralizing the C inhibitors and optimizing the antibody-initiated C attack. For further studies, the spheroid system offers a useful model.
|
Footnotes |
|---|
This work was supported by the Academy of Finland, the Sigrid Jusélius Foundation and a state subsidy to Helsinki University Central Hospital.
Accepted for publication June 5, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  S. K. Green, M. C. I. Karlsson, J. V. Ravetch, and R. S. Kerbel Disruption of Cell-Cell Adhesion Enhances Antibody-dependent Cellular Cytotoxicity: Implications for Antibody-based Therapeutics of Cancer Cancer Res., December 1, 2002; 62(23): 6891 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Inoue, M Yamakawa, and T Takahashi Expression of complement regulating factors in gastric cancer cells Mol. Pathol., June 1, 2002; 55(3): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Lindorfer, A. Nardin, P. L. Foley, M. D. Solga, A. J. Bankovich, E. N. Martin, A. L. Henderson, C. W. Price, E. Gyimesi, C. P. Wozencraft, et al. Targeting of Pseudomonas aeruginosa in the Bloodstream with Bispecific Monoclonal Antibodies J. Immunol., August 15, 2001; 167(4): 2240 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Redondo, E. Villar, J. Torres-Munoz, T. Tellez, M. Morell, and C. K. Petito Overexpression of Clusterin in Human Breast Carcinoma Am. J. Pathol., August 1, 2000; 157(2): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
), and the released
radioactivity was counted from the supernatants after 24 hours of
incubation at 37°C. In another set of experiments, the consumed C was
replaced by fresh NHS at 2, 4, and 8 hours during the 24-hour
incubation. The pulsed addition
(
) of C increased the
lysis of spheroids from 16 ± 4 to 33 ± 2.3%
(mean ± standard deviation
(SD)).
In the controls, normal rat IgG (25
µg/ml) and preimmune rabbit IgG
(S0; 50 µg/ml) were
used instead of YTH53.1B and S2, or YTH53.1B and S2 were used
separately. B: Time course of spheroid lysis.
51Cr-labeled T47D spheroids were exposed to S2 and YTH53.1
(
), S0 and Rat IgG
(
), S2
(
), YTH53.1
(
), and NHS as above
for the times indicated. During the incubation the microtumors were
isolated and placed into new tubes containing fresh serum and the
respective antibodies at 2, 4, and 8 hours. In C and D,
the lysis of the spheroids was examined for 48 and 50 hours, and fresh
Complement was added during the incubation 7 or 11 times, respectively.
The radioactivity released was counted from the supernatants. A
to D: Cell lysis was determined as the percentage of total
radioactivity: ((Released
cumulative radioactivity - spontaneous 51Cr
release)/(Total
radioactivity - spontaneous 51Cr
release)) x 100%. The
vertical bars indicate the SD of quadruplicate determinations.
Two-tailed Student's t-test; *P < 0.05;
comparison between lysis values of spheroids exposed to a single dose
and multiple doses of complement (A); ***, P <
0.001 lysis of spheroids exposed to S2, YTH53.1B
(
